Riad Sarah E, Elhelw Dalia S, Shawer Heba, El-Ekiaby Nada, Salah Ayman, Zekri Abdelrahman, Esmat Gamal, Amleh Asma, Abdelaziz Ahmed I
Pharmacology and Toxicology Department, German University in Cairo, New Cairo, Egypt.
Pharmaceutical Chemistry Department, German University in Cairo, New Cairo, Egypt.
Front Genet. 2018 Mar 20;9:93. doi: 10.3389/fgene.2018.00093. eCollection 2018.
HCV entry involves a complex interplay between viral and host molecules. During post-binding interactions, the viral E2 complexes with CD81 receptor for delivery to the tight junction proteins CLDN1 and OCLN, which aid in viral internalization. Targeting HCV entry receptors represents an appealing approach to inhibit viral infectivity. This study aimed at investigating the impact of targeting CLDN1 by microRNAs on HCV infectivity. miR-155 was previously shown to target the 3'UTR of CLDN1 mRNA. Therefore, miR-155 was used as a control in this study. analysis and luciferase reporter assay were utilized to identify potential targeting miRNAs. The impact of the identified miRNAs on CLDN1 mRNA and protein expression was examined by qRT-PCR, indirect immunofluorescence and western blotting, respectively. The role of the selected miRNAs on HCV infectivity was assessed by measuring the viral load following the ectopic expression of the selected miRNAs. miR-182 was identified and by experimental validation to target CLDN1. Both miR-155 and miR-182 inhibited CLDN1 mRNA and protein expression in infected Huh7 cells. Ectopic expression of miR-155 increased, while miR-182 reduced the viral load. In conclusion, despite repressing CLDN1, the impact of miR-155 and miR-182 on HCV infectivity is contradictory. Ectopic miR-182 expression is suggested as an upstream regulator of the entry factor CLDN1, harnessing HCV infection.
丙型肝炎病毒(HCV)的进入涉及病毒和宿主分子之间复杂的相互作用。在结合后相互作用过程中,病毒E2与CD81受体形成复合物,以便递送至紧密连接蛋白CLDN1和OCLN,后者有助于病毒内化。靶向HCV进入受体是一种抑制病毒感染性的有吸引力的方法。本研究旨在调查微小RNA靶向CLDN1对HCV感染性的影响。先前已证明miR-155靶向CLDN1 mRNA的3'UTR。因此,本研究中使用miR-155作为对照。利用分析和荧光素酶报告基因检测来鉴定潜在的靶向微小RNA。分别通过qRT-PCR、间接免疫荧光和蛋白质印迹法检测所鉴定的微小RNA对CLDN1 mRNA和蛋白质表达的影响。通过测量所选微小RNA异位表达后的病毒载量来评估所选微小RNA对HCV感染性的作用。通过实验验证鉴定出miR-182靶向CLDN1。miR-155和miR-182均抑制感染的Huh7细胞中CLDN1 mRNA和蛋白质的表达。miR-155的异位表达增加了病毒载量,而miR-182则降低了病毒载量。总之,尽管miR-155和miR-182抑制CLDN1,但它们对HCV感染性的影响是矛盾的。异位表达miR-182被认为是进入因子CLDN1的上游调节因子,可控制HCV感染。